Lerche, H: Therapeutic Targets and Perspectives in the Pharm
(Sprache: Englisch)
This compendium is set against the background of new findings about the mechanisms involved in epilepsy, considered from different perspectives. It provides a historical overview of what has been achieved and presents the current state-of-the-art treatments...
Leider schon ausverkauft
Buch
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
Produktdetails
Produktinformationen zu „Lerche, H: Therapeutic Targets and Perspectives in the Pharm “
Klappentext zu „Lerche, H: Therapeutic Targets and Perspectives in the Pharm “
This compendium is set against the background of new findings about the mechanisms involved in epilepsy, considered from different perspectives. It provides a historical overview of what has been achieved and presents the current state-of-the-art treatments in clinical practice. Regional differences in the treatment of the contributing specialists from various European countries and the United States have been taken into account; their respective guidelines are presented. This includes recommendations for children and adults, and also for the treatment of status epilepticus. Furthermore, a number of chapters deal with the mechanisms of classical and newly developed antiepileptic drugs as well as the therapeutic perspectives that arise from current research.This book is intended for current clinical practice, as a source of background information about the mechanisms of epilepsy and antiepileptic drugs, and also gives an outlook for the potential future therapeutic advances for this common disease.
Inhaltsverzeichnis zu „Lerche, H: Therapeutic Targets and Perspectives in the Pharm “
1. Introduction (H. Potschka, H. Lerche) 162. Historical development of pharmacotherapy (D. Schmidt) 202.1. AED discovery - serendipity, science or both 202.2. Bromide - an an-aphrodisiac turns out to be good for seizure control 202.3. Phenobarbital - not all hypnotics are alike 202.4. Phenytoin - the first AED discovered by preclinical testing 212.5. Carbamazepine - an AED discovered in the search for a neuroleptic 212.6. Valproic acid - a classic example of serendipity in drug discovery 222.7. Lamotrigine - an erroneous hypothesis leading to discovery of a major AED 222.8. Levetiracetam - a major AED discovered in the search for a better piracetam 222.9. Gabapentin - a major AED/analgesic with a misleading generic name 232.10. Topiramate - a potential antidiabetic agent turns out to be an antiepileptic drug 233. Current anticonvulsant therapy 263.1. Current recommendations, guidelines, and expert views of practical anticonvulsant therapy (S. Klamer, A. Singh, A. Gil-Nagel, G. Krämer, J. French, H. Lerche) 263.1.1. Guideline creation processes 263.1.2. ILAE and AAN guidelines 263.1.3. European guidelines 313.1.3.1. General considerations 313.1.3.2. Treatment of idiopathic generalized epilepsies 323.1.3.3. Treatment of focal epilepsies 333.1.3.4. Withdrawal of pharmacological treatment 343.1.3.5. Contraception and pregnancy 343.2. Current recommendations for children (J.H. Cross, G. Kurlemann) 363.2.1. Intrauterine seizures 363.2.2. Neonatal seizures 363.2.3. Acute therapy of prolonged epileptic seizures 363.2.4. Febrile convulsions 373.2.5. Seizures in infancy: an overview 383.2.6. Infantile spasms and West syndrome 383.2.7. Dravet syndrome 383.2.8. Benign focal epilepsies 383.2.9. Continuous spike wave of slow sleep/Landau-Kleffner syndrome 393.2.10. Lesional and presumed lesional focal epilepsy 393.2.11. Lennox-Gastaut syndrome 433.2.12. Idiopathic generalized seizures and epilepsy syndromes 433.3. Current recommendations for status epilepticus (M. Holtkamp,
... mehr
A.O. Rossetti, S. Shorvon, E. Trinka) 453.3.1. The lack of licensing of i.v. drugs 453.3.2. Optimizing care across Europe 453.3.3. General recommendations for treatment 453.3.4. Treatment protocol 473.3.5. Treatment failure 494. Recently marketed drugs (B.J. Steinhoff, C.E. Elger, E. Perucca) 524.1. Lacosamide (LCM) 524.2. Eslicarbazepine acetate (ESL) 544.3. Retigabine (RTG) 564.4. Other compounds in clinical development 585. Mechanisms of action and future perspectives 625.1. Targets and mechanisms of action of classical anticonvulsant drugs (G.J. Sills) 625.1.1. Voltage-gated sodium channels 625.1.2. Voltage-gated calcium channels 635.1.3. GABAA receptors 645.2. Mechanisms of recently marketed drugs and drugs in clinical development (T.V. Wuttke, H. Potschka, H.S. White, H. Lerche) 655.2.1. Eslicarbazepine acetate 655.2.2. Ganaxolone 675.2.3. Lacosamide 675.2.4. Lamotrigine 685.2.5. Levetiracetam/Brivaracetam 685.2.6. Perampanel 695.2.7. Pregabalin 705.2.8. Retigabine 705.2.9. Rufinamide 715.2.10. Stiripentol 715.2.11. Topiramate 715.2.12. YKP-3089 725.2.13. Zonisamide 725.3. Mechanisms of drug resistance and consequences for drug development (H. Potschka) 765.3.1. Mechanisms of drug resistance 775.3.2. Consequences for drug development and therapy 805.4. Mechanisms of status epilepticus and therapeutic implications (M. Holtkamp, A.O. Rossetti) 825.4.1. Animal models resembling status epilepticus 825.4.2. Development and maintenance of status epilepticus 835.4.3. Consequences of status epilepticus 835.4.4. Therapeutic implications 845.5. Targets for antiepileptogenesis 865.5.1. Overview (A. Pitkänen) 865.5.1.1. Terminology 865.5.1.2. Identification of molecular targets: "omics" vs. serendipity? 865.5.1.3. Choosing the treatment: the same for all etiologies and patients? 875.5.1.4. Choosing the treatment: monotherapy vs. polytherapy? 895.5.1.5. Time of initiation of treatment: does it matter? 895.5.2. Acquired channelopathies (A.J. Becker, C. Bernard) 905.5.2.1. A-type potassium channels 915.5.2.2. Hyperpolarization-activated cation channels 915.5.2.3. T-type calcium channels 915.5.3. Inflammation (T. Ravizza, M. Rizzi, J. VelíSková, A-M. Vezzani) 945.5.3.1. Activation of inflammatory pathways in epileptogenesis 945.5.3.2. Mechanisms of hyperexcitability 965.5.4. Blood-brain barrier and angiogenesis (M. Friedman, M. Lerner-Natoli) 985.5.4.1. The blood-brain barrier 985.5.4.2. BBB dysfunction, astrocytic transformation and epileptogenesis 995.5.4.3. Pathological angiogenesis in the epileptic focus 995.5.4.4. The vicious circle of angiogenesis/ epileptogenesis 995.5.4.5. Major steps and actors of angiogenesis 995.5.4.6. VEGF/VEGFR-2: a complex system for multiple effects 1005.5.4.7. Which strategies to protect the BBB? 1015.6. Perspectives of pharmacogenetics: targets and side effects (F. Zimprich, S. Sisodiya) 1025.6.1. Targets 1025.6.2. Side effects 1035.7. Perspectives of imaging (M. Koepp) 1065.7.1. Prediction of adverse effects 1065.7.2. Pharmacoresistance 107Index 111¿
... weniger
Bibliographische Angaben
- Autoren: Holger Lerche , Heidrun Potschka
- 112 Seiten, 20 Abbildungen, Maße: 17,7 x 24,6 cm, Gebunden, Englisch
- Verlag: Uni-Med Verlag Ag
- ISBN-10: 1848152000
- ISBN-13: 9781848152007
- Erscheinungsdatum: 28.08.2013
Sprache:
Englisch
Kommentar zu "Lerche, H: Therapeutic Targets and Perspectives in the Pharm"
0 Gebrauchte Artikel zu „Lerche, H: Therapeutic Targets and Perspectives in the Pharm“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Lerche, H: Therapeutic Targets and Perspectives in the Pharm".
Kommentar verfassen